SECsense Logo

APTOSE Biosciences Inc. 8-K Report: Key Developments & Financial Insights

$APTO
Form 8-K
Filed on: 2025-01-13
Source
APTOSE Biosciences Inc. 8-K Report: Key Developments & Financial Insights

Based on the provided section of the financial report, here are the key pieces of information and insights extracted:

  1. Entity Information:
  • Company Name: APTOSE Biosciences Inc.
  • CIK Number: 0000882361
  • SEC File Number: 001-32001
  • Tax ID: 98-1136802
  • Address: 66 Wellington Street West, Suite 5300, TD Bank Tower Box 48, Toronto, ON, M5K 1E6, Canada
  • Contact Number: (310) 849-8060
  1. Filing Type:
  • The report is an 8-K filing, which typically discloses significant events that shareholders should know about.
  1. Filing Date:
  • The report is dated January 13, 2025.
  1. Financial Metrics:
  • Common Shares: The company has Common Shares with no par value listed under the ticker symbol "APTO" on NASDAQ.
  1. Contextual Information:
  • The context indicates that the report is for a specific date, January 13, 2025, which suggests it reflects events or financial conditions as of that date.
  • It uses USD as the currency for its financial figures.
  1. XBRL Details:
  • The report is structured in XBRL format, which is used for digital financial reporting, allowing for easier data extraction and analysis.

Insights:

  • The filing of an 8-K indicates that there may be important developments concerning APTOSE Biosciences, which could affect its stock performance or investor perception.
  • The presence of "Common Shares, no par value" suggests that the company does not have a stated value for its shares, which can be common for biotech firms that may focus on growth rather than established capital structures.
  • The report being filed in early 2025 may indicate upcoming strategic initiatives or events that could be significant for stakeholders, particularly given the nature of APTOSE's business in the biotechnology sector.

This extracted information can provide insights for investors and analysts regarding the company's current status and potential future developments.